Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nova Eye MedicalELXMF -0.03%52 3-Year EPS without NRI Growth Rate is 37.70% as of Jun. 2026, which is 435% above its 10-year median of 7.05. GuruFocus rates ELXMF with a GF Score™ of 52/100 and a GF Value™ of $0.02. The stock has 3 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Nova Eye Medical ranks better than 82.78% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 37.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 12.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Nova Eye Medical was 75.00% per year. The lowest was -115.40% per year. And the median was 7.05% per year.
Nova Eye Medical (OTCPK:ELXMF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Nova Eye Medical 3-Year EPS without NRI Growth Rate Related Terms
ELXMF vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Nova Eye Medical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's 3-Year EPS without NRI Growth Rate falls into.
Nova Eye Medical 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 37.70% mean?
Nova Eye Medical (ELXMF) has a 3-Year EPS without NRI Growth Rate of 37.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Nova Eye Medical and its competitors. This is 435% above median its historical median of 7.05. According to the industry distribution chart, Nova Eye Medical ranks #114 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 17.2%.
Is Nova Eye Medical's 3-Year EPS without NRI Growth Rate too high?
Nova Eye Medical's current 3-Year EPS without NRI Growth Rate of 37.70% is 435% above median its 10-year median of 7.05. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Nova Eye Medical's value of 37.70% is 368.3% above this industry median. Based on the distribution chart, Nova Eye Medical ranks #114 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nova Eye Medical has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #114 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places Nova Eye Medical in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Nova Eye Medical's value of 37.70% is 368.3% above this benchmark. While the company's 10-year median is 7.05 vs. the industry median of 8.05, Nova Eye Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Eye Medical's current 3-Year EPS without NRI Growth Rate of 37.70% is 368.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Nova Eye Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current 3-Year EPS without NRI Growth Rate is 37.70%, which is 435% above median its own 10-year median of 7.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current 3-Year EPS without NRI Growth Rate of 37.70%. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 37.70%, which is 435% above median its 10-year median of 7.05 and 368.3% above the Medical Devices & Instruments industry median of 8.05. Nova Eye Medical's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current 3-Year EPS without NRI Growth Rate is 37.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ELXMF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.
Key valuation signals for ELXMF:
3-Year EPS without NRI Growth Rate: 37.70% (435% above median its 10-year median of 7.05)
GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
Industry Position: 368.3% above the Medical Devices & Instruments median (#114 of 662)
No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
52GF Score
Get the complete analysis for ELXMF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELXMF has been successfully added to your 
